Cognition rises after FDA backs late-stage trial plan for dementia drug
BUZZ-Cognition rises after FDA backs late-stage trial plan for dementia drug ** Shares of drug developer Cognition Therapeutics CGTX.O rise 7% to 79 cents premarket
** Cognition Therapeutics says the US FDA supported the company's plan to test its experimental drug in a large study of people with dementia with lewy bodies
** The nine-month late-stage study will compare a 100-milligram daily dose of zervimesine with a placebo in people with mild-to-moderate disease
** Dementia with lewy bodies is a brain disease that can cause memory loss, confusion, hallucinations and movement problems
** The main goal will be whether the drug reduces hallucinations and delusions. The study will also assess whether it helps patients manage everyday activities
** As of last close, CGTX stock was down 44.7% YTD
(Reporting by Padmanabhan Ananthan)
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB